Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case–control study using Lactobacillus rhamnosus BMX 54 as adjuvant treatment against bacterial vaginosis

Archives of Gynecology and Obstetrics

Volumn 293, Issue 1, 2016, Pages 101-107

  Recine, Nadia ^a   Palma, Ettore ^a   Domenici, Lavinia ^a   Giorgini, Margherita ^a   Imperiale, Ludovica ^a   Sassu, Carolina ^a   Musella, Angela ^a   Marchetti, Claudia ^a   Muzii, Ludovico ^a   Benedetti Panici, Pierluigi ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bacterial vaginosis; Lactobacillus rhamnosus BMX54; Probiotics; Vaginal flora

Indexed keywords

BMX 54; METRONIDAZOLE; PROBIOTIC AGENT; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; IMMUNOLOGICAL ADJUVANT;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HUMAN; INFECTION CONTROL; LACTOBACILLUS RHAMNOSUS; MAJOR CLINICAL STUDY; NONHUMAN; PROSPECTIVE STUDY; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; VAGINA FLORA; VAGINA PH; VAGINITIS; AGED; EVALUATION STUDY; INTRAVAGINAL DRUG ADMINISTRATION; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; TREATMENT OUTCOME; VAGINA; VAGINOSIS, BACTERIAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVAGINAL; ADULT; AGED; ANTI-INFECTIVE AGENTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LACTOBACILLUS RHAMNOSUS; METRONIDAZOLE; MICROBIOTA; MIDDLE AGED; PROBIOTICS; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME; VAGINA; VAGINOSIS, BACTERIAL;

EID: 84952862212     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-015-3810-2     Document Type: Article

References (33)

1. CDC Centers for Disease Control and Prevention (2006) Pathogenesis of abnormal vaginal Xora. Am J Obstet Gynecol 182:872–878
2. Ventolini G (2015) Vaginal Lactobacillus: biofilm formation in vivo—clinical implications. Int J Womens Health 7:243–247
3. Martin DH (2012) The microbiota of the vagina and its influence on women’s health and disease. Am J Med Sci 343:2–9
4. Institute of Medicine (US) Forum on Microbial Threats (2012) The social biology of microbial communities: workshop summary. National Academies Press (US), Washington (DC)
5. Eschenbach DA (1993) History and review of bacterial vaginosis. Am J Obstet Gynecol 169:441–445
6. Hill GB (1993) The microbiology of bacterial vaginosis. Am J Obstet Gynecol 169:450–454
7. Holst E (1987) Bacterial vaginosis microbiological and clinical findings. Eur J Clin Microbiol 6:536–541
8. Kumar Nikhil, Behera Beauty, Sagiri Sai S, Pal Kunal, Ray Sirsendu S, Roy Saroj (2011) Bacterial vaginosis: etiology and modalities of treatment—a brief note. J Pharm Bioallied Sci 3:496–503
9. Antonio MA, Hawes SE, Hillier SL (1999) The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species. J Infect Dis 180:1950–1956
10. Donders GG (2007) Definition and classification of abnormal vaginal flora. Best Pract Res Clin Obstet Gynaecol 21:355–373
11. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KKb(1983). Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 74:14–22
12. Hay PE, Lamont RF, Taylor-Robinson D, Morgan DJ, Ison C, Pearson J (1994) Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. BMJ 308:295–298
13. Ison CA, Hay PE (2002) Validation of a simplified grading of Gram stained vaginal smears for use in genitourinary medicine clinics. Sex Transm Infect 78:413–415
14. Nugent RP, Krohn MA, Hillier SL (1991) Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 29:297–301
15. Vicariotto F, Mogna L, Del Piano M (2014) Effectiveness of the two microorganisms Lactobacillus fermentum LF15 and Lactobacillus plantarum LP01, formulated in slow-release vaginal tablets, in women affected by bacterial vaginosis: a pilot study. J Clin Gastroenterol 48:S106–S112
16. Parent D, Bossens M, Bayot D, Kirkpatrick C, Graf F (1996) Therapy of bacterial vaginosis using exogenously-applied Lactobacillus aciophili and a low dose of estriol: a placebo-controlled multicentric clinical trial. Arzneimitell Forschung 46:68–73
17. Hay PE (1998) Recurrent bacterial vaginosis. Dermatol Clin 16:769–773, xii–xiii
18. Carey JC, KlebanoV MA, Hauth JC, Hillier SL, Thom EA, Ernest JM, Heine RP et al (2000) Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 342:534–540
19. Bradshaw CS, Morton AN, Hocking J et al (2006) High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 193:1478–1486
20. Mastromarino P, Vitali B, Mosca L (2013) Bacterial vaginosis: a review on clinical trials with probiotics. New Microbiol 36:229–238
21. Homayouni A, Bastani P, Ziyadi S, Mohammad-Alizadeh-Charandabi S, Ghalibaf M, Mortazavian AM, Mehrabany EV (2014) Effects of probiotics on the recurrence of bacterial vaginosis: a review. J Low Genit Tract Dis 18:79–86
22. Marcone V, Calzolari E, Bertini M (2008) Effectiveness of vaginal administration of Lactobacillus rhamnosus following conventional metronidazole therapy: how to lower the rate of bacterial vaginosis recurrences. New Microbiol 31:429–433
23. Cadieux P, Burton J, Gardiner G, Braunstein I, Bruce AW, Kang CY, Reid G (2002) Lactobacillus strains and vaginal ecology. JAMA 287:1940–1941
24. Anukam K, Osazuwa E, Ahonkhai I, NgwuM Osemene G, Bruce AW et al (2006) Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect 8:1450–1454
25. YaW Reifer C, Miller LE (2010) Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebocontrolled study. Am J Obstet Gynecol 203:120–125
26. Reid GK, Mills AP, Bruce AW (1994) Implantation of Lactobacilli Casei var-rhamnosus into the vagina. Lancet 344:1229
27. Reid G, Burton J (2002) Use of lactobacillus to prevent infection by pathogenic bacteria. Microbes Infect 4:319–324
28. Recine N, Musciola A, Moreira E. The benefits of topical vaginal therapy with Lactobacillus casei sub-rhamnosus in preventing bacterial vaginosis relapses. Communications and Posters for the X National IBAT Conference 2011, Naples, 26–28 Jan, 18(suppl 1)
29. Rossi A, Rossi T, Bertini M (2010) The use of Lactobacillus rhamnosus in the therapy of bacterial vaginosis. Evaluation of clinical efficacy in a population of 40 women treated for 24 months. Arch Gynecol Obstet 281:1065–1069
30. Bertini M (2013) Is Lactobacillus Rhamnosus BMX 54 vaginal application a good strategy to counteract bacterial vaginosis recurrences? 18th World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI), 24–27 Oct, 2013, Vienna, Austria, Code 1766, pp 339–345
31. Parma M, Stella Vanni V, Bertini M, Candiani M (2014) Probiotics in the prevention of recurrences of bacterial vaginosis. Altern Ther Health Med 20:52–57
32. Mc Lean N, Rosenstein IJ (2000) Characterisation and selection of a Lactobacillus species to re- colonise the vagina of women with recurrent bacterial vaginosis. J Med Microbiol 49:543–552
33. Gardiner GE, Heinemann C, Bruce AW, Beuerman D, Reid G (2002) Persistence of Lactobacillus fermentum RC-14 and Lactobacillus rhamnosus GR-1 but not L. Rhamnosus GG in the human vagina as demonstrated by randomly amplified polymorphic DNA. Clin Diagn Lab Immunol 9:92–96